Share This:
https://ntp.niehs.nih.gov/go/20968

TDMS Study 96003-05 Pathology Tables

NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01
Route: GAVAGE                                                                                                     Time: 13:50:46

                                                          FINAL#1/MICE




       Facility:  BIORELIANCE

       Chemical CAS #:  106-95-6

       Lock Date:  10/18/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 2            1            2                                      1           
    Natural Death                                                                             1                         1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                13           14           13           14           15           13           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (14)         (15)         (15)         
      Lymphoma Malignant                               1 (7%)       1 (7%)                                              1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (14)         (15)         (15)         
      Lymphoma Malignant                                                                                                1 (7%)      
   Adrenal Medulla                                    (15)         (15)         (15)         (14)         (15)         (15)         
      Lymphoma Malignant                                                                                                1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                         (1)                                    (1)                       (1)          
      Sarcoma                                                                                 1 (100%)                              
      Abdominal, Sarcoma                                                                                                1 (100%)    
      Pelvic, Fibrosarcoma                             1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                                      (1)                                    (1)                       
      Lymphoma Malignant                                            1 (100%)                                                        
   Lymph Node, Mandibular                             (15)         (14)         (15)         (14)         (15)         (13)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Lymph Node, Mesenteric                             (15)         (14)         (15)         (12)         (15)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Lymph Node, Mediastinal                            (15)         (14)         (15)         (14)         (15)         (14)         
      Lymphoma Malignant                                            1 (7%)                                              1 (7%)      
   Spleen                                             (15)         (15)         (15)         (14)         (15)         (15)         
      Lymphoma Malignant                               1 (7%)       1 (7%)                                              1 (7%)      
   Thymus                                             (14)         (14)         (14)         (14)         (15)         (14)         
      Lymphoma Malignant                               1 (7%)                                                           1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (14)         (15)         (15)         
      Subcutaneous Tissue, Osteosarcoma                1 (7%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (2)          (1)          (1)                                                 
      Osteosarcoma                                                               1 (100%)                                           
      Mandible, Osteosarcoma                                        1 (100%)                                                        
      Vertebra, Osteosarcoma                           1 (50%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Lymphoma Malignant                                                                                                1 (7%)      
      Osteosarcoma, Metastatic, Skin                   1 (7%)                                                                       
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Lymphoma Malignant                               1 (7%)       1 (7%)                                              1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             4           2           1           1                       2               
     Total Primary Neoplasms                            4           2           1           1                       2               
                                                                                                                                    
   Total Animals with Benign Neoplasms                                                                                              
     Total Benign Neoplasms                                                                                                         
                                                                                                                                    
   Total Animals with Malignant Neoplasms               4           2           1           1                       2               
     Total Malignant Neoplasms                          4           2           1           1                       2               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1                                                                           
     Total Metastatic Neoplasm                          1                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) MALE                 VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                                   1                                      1                        
    Moribund Sacrifice                                                                                     1                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           14           15           15           13           15           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (14)         (15)         
      Squamous Cell Papilloma                                                                 1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) MALE                 VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                              (1)                                                 
      Rhabdomyosarcoma                                                           1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Alveolar/Bronchiolar Adenoma                                                            1 (7%)       1 (7%)                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/26/01  
Route: GAVAGE                                                                                                     Time: 13:50:46  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) MALE                 VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)                                     1           2           1                           
     Total Primary Neoplasms                                                    1           2           1                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                                                      2           1                           
     Total Benign Neoplasms                                                                 2           1                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       1                                                   
     Total Malignant Neoplasms                                                  1                                                   
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------